New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation

[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation].:

Related Articles

[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation].

Bull Cancer. 2020 Sep 22;:

Authors: Corbaux P, Sabatier R

PMID: 32977934 [PubMed - as supplied by publisher]